International Journal of Hematology

, Volume 98, Issue 6, pp 716–718

Improving cytopenia with splenic artery embolization in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab

  • Suresh K. Krishnan
  • Anita Hill
  • Peter Hillmen
  • Louise M. Arnold
  • Gemma L. Brooksbank
  • Alex Wood
  • Andrew Scarsbrook
  • Mervyn H. Davies
  • Richard J. Kelly
Case Report

Abstract

Paroxysmal nocturnal hemoglobinuria is a rare acquired stem cell disorder characterized by intravascular hemolysis, aplasia and an increased risk of thrombosis. We describe a patient under treatment with the anti-complement antibody eculizumab who developed pancytopenia, requiring blood transfusions, due to massive splenomegaly. The patient underwent two separate splenic embolizations, which reduced the size of the spleen and improved his blood count to the point that blood transfusions were no longer necessary. Splenic embolization was chosen over splenectomy due to the potential postoperative complications of splenectomy, especially that of thrombosis.

Keywords

Paroxysmal nocturnal hemoglobinuria Eculizumab Splenic artery embolization Cytopenia 

References

  1. 1.
    Kinoshita T, Ohishi K, Takeda J. GPI-anchor synthesis in mammalian cells: genes, their products, and a deficiency. J Biochem. 1997;122:251–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Rotoli B, Luzzatto L. Paroxysmal nocturnal hemoglobinuria. Baillieres Clin Haematol. 1989;2:113–38.PubMedCrossRefGoogle Scholar
  3. 3.
    Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. New Engl J Med. 1995;333:1253–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117:6786–92.PubMedCrossRefGoogle Scholar
  5. 5.
    Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extra cellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653–62.PubMedCrossRefGoogle Scholar
  6. 6.
    Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and Management of paroxysmal nocturnal hemoglobinuria. Br J Haematol. 2007;137:181–92.PubMedCrossRefGoogle Scholar
  7. 7.
    Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699–709.PubMedCrossRefGoogle Scholar
  8. 8.
    Mayo VM, Mukhina GL, Garrett ES, Brodsky RA. Natural history of paroxysmal nocturnal hemoglobinuria using modern diagnostic assays. Br J Haematol. 2004;126:133–8.CrossRefGoogle Scholar
  9. 9.
    Nishimura J, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193–207.CrossRefGoogle Scholar
  10. 10.
    Socié G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, et al. Paroxysmal nocturnal hemoglobinuria: long-term follow-up and prognostic factors. Lancet. 1996;348:573–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33:1389–401.PubMedCrossRefGoogle Scholar
  12. 12.
    Risitano AM, Notaro R, Marando L, Serio B, Ranaldi D, Seneca E, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113:4094–100.PubMedCrossRefGoogle Scholar
  13. 13.
    Hill A, Rother RP, Arnold L, Kelly R, Cullen MJ, Richards SJ, et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extra vascular hemolysis occurring through C3 opsonisation. Haemtologica. 2010;95:567–73.CrossRefGoogle Scholar
  14. 14.
    Risitano AM, Marando L, Seneca E, Rotoli B. Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab. Blood. 2008;112:449–51.PubMedCrossRefGoogle Scholar
  15. 15.
    Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicentre phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Rodeghiero F, Ruggeri M. Short- and long-term risks of splenectomy for benign hematological disorders: should we revisit the indications? Br J Haematol. 2012;158:16–29.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2013

Authors and Affiliations

  • Suresh K. Krishnan
    • 1
  • Anita Hill
    • 1
  • Peter Hillmen
    • 1
  • Louise M. Arnold
    • 1
  • Gemma L. Brooksbank
    • 1
  • Alex Wood
    • 1
  • Andrew Scarsbrook
    • 3
  • Mervyn H. Davies
    • 2
  • Richard J. Kelly
    • 1
  1. 1.Department of Hematology/OncologySt-James University HospitalLeedsUK
  2. 2.Department of HepatologySt-James University HospitalLeedsUK
  3. 3.Department of RadiologySt-James University HospitalLeedsUK

Personalised recommendations